What this service is:

Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries.

What it helps you do:

• Follow major actions at the federal and state level that focus on intellectual property/patent issues, drug pricing and reimbursement, FDA oversight, and Federal Trade Commission antitrust enforcement.
• Keep current with marketplace news on the forces behind escalating costs and the responses from the public and private sectors.
• Understand how health plans, pharmacy benefit managers, and employers develop and apply drug cost-containment strategies and modifications to health plan benefits.
• Stay tuned in with "hot links" to important full-text documents on the Web, such as Federal Register notices, court decisions, and government reports.
• Save hours of reading time with analytical articles on emerging case law and current litigation by practicing attorneys.
• Rely on reporting that is objective and independent, as well as timely.

Product Structure

Notification: current reports providing news and developments

Formats and Frequency

Web notification is published continually. Print notification is available weekly. Print current reports are indexed every six months, cumulating annually. Web current reports are archived to 1/17/2003, with archive coverage of Pharmaceutical Law & Policy Report since 7/12/2001. E-mail summaries, providing the highlights and table of contents for each report, with URLs to full text articles and documents are also available.

• Reforms to Hatch-Waxman Act
• Fraud and abuse investigations
• FDA regulation of drug company advertising and marketing
• FTC antitrust enforcement actions
• Growth of generic drugs
• State Medicaid formularies
• Biotechnology patents
• Medicare drug benefit debate
• Drug pricing lawsuits by states and consumers